Clinical Trial Search

Primary: Change in the Percentage of White Matter Hyperintensity (WMH) Lesion Volume on FLAIR MRI in RVCL Patients — 31.3 Percent (%)

Primary: Visual Acuity — 16.8; 14.5; 19.1; 15.3 letters on ETDRS Visual Acuity Chart

Primary: Number of Participants With Ocular Adverse Events in the Study Eye — 51; 64; 63; 60 participants

Primary: Best Corrected Visual Acuity Change From Baseline at All Visits — 10.5; 15.1 ETDRS letters

Primary: Tabulation of Adverse Events — 13 adverse events

Primary: Incidence and Severity of Ocular and Non-ocular Adverse Events. — 17; 12; 37; 35 participants

Primary: Commonly Reported and Notable Adverse Events — 1; 2; 2; 3 participants

Primary: Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence…

Primary: Trend of Change From Baseline in the Best Corrected Visual Acuity (BCVA) Scores From Month 7 to Month 15 — 17.5; 19.7; 18.7; 21.0 Letters — p=0.5091

Primary: Total Number of Intravitreal Injections Over a 12 Month Period — 8.7; 9.5 injections

Primary: The Primary Outcome is the Comparison Between the Minocycline and Placebo Groups of the Mean Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at 12 Months…

Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA

Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…

Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05

Primary: Incidence of Serious Adverse Events. — 17 number of serious adverse events

Primary: Incidence and Severity of Ocular and Systemic Adverse Events — 1; 0; 0; 1 participants

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline — 12.3 Letters

Primary: Proportion of Subjects With BCVA Gain of 15 or More Letters From Baseline in the Study Eye — 1; 1; 1 Participants

Primary: The Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to…

Primary: Mean Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at 12 Months Compared to Baseline. — 5.3; 13.0 ETDRS letters

Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter Score — 64; 9 percentage of participants — p=< 0.0001

Primary: New DWI Lesion(s) — 1.2; 1.0; 0.6 Number of new lesions

Primary: Number of Participants Experiencing Adverse Events — 6; 7; 12 Participants

Primary: Mean Change From Baseline BCVA — 14; 5 Letters (ETDRS chart)

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 2; 21; 1; 0 Participants

Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants…

Primary: Mean Change in Visual Acuity: BCVA Change at Month 6 Compared to Baseline in Patients With Visual Impairment Due to Branch Retinal Vein Occlusion (BRVO) — 59.5; 56.6…

Primary: Number of Participants With Successful Treatment of ROP — 11; 14; 21; 9 Participants

Primary: Percentage of Participants With Improvement in DRSS by ≥ 2 Steps at 48 Weeks of Treatment in the Study Eye — 0.0; 1.9 percentage of participants

Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer